We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Elevance Health (ELV) Q4 Earnings
Read MoreHide Full Article
In its upcoming report, Elevance Health (ELV - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $3.07 per share, reflecting a decline of 20.1% compared to the same period last year. Revenues are forecasted to be $49.53 billion, representing a year-over-year increase of 10.1%.
The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Elevance Health metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenues- Service fees' at $2.13 billion. The estimate indicates a year-over-year change of +4.7%.
The collective assessment of analysts points to an estimated 'Revenues- Premiums' of $40.69 billion. The estimate indicates a year-over-year change of +12.3%.
Analysts' assessment points toward 'Revenues- Net investment income' reaching $469.69 million. The estimate suggests a change of -10.9% year over year.
Based on the collective assessment of analysts, 'Revenues- Product revenue' should arrive at $6.82 billion. The estimate suggests a change of +1.5% year over year.
It is projected by analysts that the 'Total Medical Membership' will reach 45.40 million. Compared to the present estimate, the company reported 45.73 million in the same quarter last year.
The consensus estimate for 'Medical Membership - Medicare - Medicare Advantage' stands at 2.24 million. Compared to the current estimate, the company reported 2.07 million in the same quarter of the previous year.
Analysts predict that the 'Medical Membership - Medicaid' will reach 8.60 million. The estimate is in contrast to the year-ago figure of 8.92 million.
The consensus among analysts is that 'Medical Membership - Federal Employees Health Benefits' will reach 1.63 million. The estimate compares to the year-ago value of 1.66 million.
The combined assessment of analysts suggests that 'Medical Membership - Total Medicare' will likely reach 3.11 million. The estimate compares to the year-ago value of 2.96 million.
Analysts expect 'Medical Membership - Commercial Risk-Based - Individual' to come in at 1.33 million. The estimate compares to the year-ago value of 1.29 million.
Analysts forecast 'Benefit Expense Ratio' to reach 93.4%. The estimate compares to the year-ago value of 92.4%.
According to the collective judgment of analysts, 'Medical Membership - Commercial Fee-Based' should come in at 27.08 million. The estimate compares to the year-ago value of 27.20 million.
Shares of Elevance Health have demonstrated returns of +8.4% over the past month compared to the Zacks S&P 500 composite's +0.6% change. With a Zacks Rank #4 (Sell), ELV is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Elevance Health (ELV) Q4 Earnings
In its upcoming report, Elevance Health (ELV - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $3.07 per share, reflecting a decline of 20.1% compared to the same period last year. Revenues are forecasted to be $49.53 billion, representing a year-over-year increase of 10.1%.
The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Elevance Health metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenues- Service fees' at $2.13 billion. The estimate indicates a year-over-year change of +4.7%.
The collective assessment of analysts points to an estimated 'Revenues- Premiums' of $40.69 billion. The estimate indicates a year-over-year change of +12.3%.
Analysts' assessment points toward 'Revenues- Net investment income' reaching $469.69 million. The estimate suggests a change of -10.9% year over year.
Based on the collective assessment of analysts, 'Revenues- Product revenue' should arrive at $6.82 billion. The estimate suggests a change of +1.5% year over year.
It is projected by analysts that the 'Total Medical Membership' will reach 45.40 million. Compared to the present estimate, the company reported 45.73 million in the same quarter last year.
The consensus estimate for 'Medical Membership - Medicare - Medicare Advantage' stands at 2.24 million. Compared to the current estimate, the company reported 2.07 million in the same quarter of the previous year.
Analysts predict that the 'Medical Membership - Medicaid' will reach 8.60 million. The estimate is in contrast to the year-ago figure of 8.92 million.
The consensus among analysts is that 'Medical Membership - Federal Employees Health Benefits' will reach 1.63 million. The estimate compares to the year-ago value of 1.66 million.
The combined assessment of analysts suggests that 'Medical Membership - Total Medicare' will likely reach 3.11 million. The estimate compares to the year-ago value of 2.96 million.
Analysts expect 'Medical Membership - Commercial Risk-Based - Individual' to come in at 1.33 million. The estimate compares to the year-ago value of 1.29 million.
Analysts forecast 'Benefit Expense Ratio' to reach 93.4%. The estimate compares to the year-ago value of 92.4%.
According to the collective judgment of analysts, 'Medical Membership - Commercial Fee-Based' should come in at 27.08 million. The estimate compares to the year-ago value of 27.20 million.
View all Key Company Metrics for Elevance Health here>>>Shares of Elevance Health have demonstrated returns of +8.4% over the past month compared to the Zacks S&P 500 composite's +0.6% change. With a Zacks Rank #4 (Sell), ELV is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .